Nifekalant for Atrial Tachycardia-Induced Cardiogenic Shock in a Patient With Severe Left Ventricular Systolic Dysfunction

尼非卡兰用于治疗伴有严重左心室收缩功能障碍的房性心动过速诱发的心源性休克

阅读:1

Abstract

BACKGROUND: Atrial tachycardia (AT) during acute heart failure with reduced left ventricular ejection fraction (LVEF) can worsen hemodynamics. Antiarrhythmic drugs are limited by negative inotropic effects. CASE SUMMARY: A 55-year-old man with idiopathic dilated cardiomyopathy was admitted with worsening heart failure under sustained AT. His LVEF had declined to 12%. Multiple ATs caused resistance to inotropes and diuretics. Repeated electrical cardioversion with intravenous amiodarone failed owing to recurrent ATs triggered by premature atrial contractions, leading to cardiogenic shock. Intravenous nifekalant and digoxin were administered for rhythm and rate control. After electrical cardioversion, premature atrial contractions no longer induced AT. Continuous nifekalant maintained sinus rhythm, allowing recovery from shock without mechanical support. Catheter ablation, cardiac resynchronization therapy, and oral sotalol achieved long-term rhythm control. The patient was discharged on day 96. DISCUSSION: Nifekalant, a selective delayed rectifier potassium current blocker, prolongs refractoriness with minimal inotropic effect, stabilizing rhythm and bridging to definitive therapy. TAKE-HOME MESSAGE: Nifekalant may be effective for refractory AT in patients with severely reduced LVEF and hemodynamic instability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。